Drug Profile
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy - Shengyan Pharmaceutical Technology
Alternative Names: BCMA-CD38 Bispecific CAR-Modified T Cells; BCMA-CD38 bispecific CAR-T cells; BM38 bivalent CAR-T cellsLatest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Shengyan Pharmaceutical Technology
- Developer Shengyan Pharmaceutical Technology; Wuhan Union Hospital
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in China (Parenteral)
- 07 Dec 2019 Efficacy and adverse events data from a phase-I trial in Multiple myeloma presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2019)
- 15 Jun 2019 Efficacy and safety data from a phase I trial in Multiple myeloma presented at the 24th Congress of the European Haematology Association (EHA-2019)